Pharmacogenetic guidelines and decision support tools for depression treatment: application to late-life

Author:

Chang Donald D1,Eyre Harris A2345,Abbott Ryan67,Coudreaut Michael8,Baune Bernhard T5,Shaman Jeffrey A9,Lavretsky Helen7,Lenze Eric J10,Merrill David A7,Singh Ajeet B3,Mulsant Benoit H1112,Reynolds Charles F13,Müller Daniel J1112,Bousman Chad14

Affiliation:

1. School of Medicine, University of Queensland-Ochsner Clinical School, Brisbane, Queensland, 4072, Australia

2. Innovation Institute, Texas Medical Center, Houston, TX 77006, USA

3. IMPACT SRC, School of Medicine, Deakin University, Geelong, Victoria, 3220, Australia

4. Department of Psychiatry, University of Melbourne, Melbourne, Victoria, 3003, Australia

5. Discipline of Psychiatry, University of Adelaide, Adelaide, South Australia, 5055, Australia

6. University of Surrey, Surrey, GU2 7XH, UK

7. David Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA 90095, USA

8. Department of Psychiatry, Intermountain Healthcare, Salt Lake City, UT 84102, USA

9. Coriell Life Sciences, Philadelphia, PA 19112, USA

10. Department of Psychiatry, Washington University, St Louis, MO 63130, USA

11. Department of Psychiatry, University of Toronto, Toronto, ON, M5S 3H7, Canada

12. Campbell Family Mental Health Research Institute, Centre for Addiction & Mental Health, Toronto, ON, M5S 3H7, Canada

13. Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA 15260, USA

14. Departments of Medical Genetics, Psychiatry, & Physiology & Pharmacology, University of Calgary, Calgary, AB, AN T2N 1N4, Canada

Abstract

Late-life depression (LLD) is a major depressive disorder that affects someone after the age of 60 years. LLD is frequently associated with inadequate response and remission from antidepressants, in addition to polypharmacy. Pharmacogenetics offers a promising approach to improve clinical outcomes in LLD via new discoveries determining the genetic basis of response rates and side effects, as well as the development of tailored pharmacogenetic-based decision support tools. This invited review evaluates the LLD pharmacogenetic evidence base and the extent to which this was incorporated into existing commercial decision support tools and clinical pharmacogenetic guidelines.

Publisher

Future Medicine Ltd

Subject

Pharmacology,Genetics,Molecular Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3